Our vision
At Galibra Neuroscience, our mission is to lead innovation in gene therapy for GABA disorders.
We are committed to the translation of cutting-edge science to meet urgent patient needs.
We aim to empower lives and set new standards for excellence in personalized healthcare.
About Us
GALIBRA NEUROSCIENCE
Galibra Neuroscience was founded in 2023 by a clinician and a scientist at Boston Children’s Hospital affiliated with Harvard Medical School. Our founders have over 25 years of experience in clinical care and translational research. We are directing our knowledge to improve patient lives.
Our Science
GABA (gamma-aminobutyric acid) is the major brain inhibitory neurotransmitter that keeps our neural communication in check.
GABA is highly regulated (i.e., balanced), where over 20 genes are directly involved in GABA synthesis, neurotransmission, degradation, and re-uptake in healthy brains.
Variants of these GABA-related genes lead to GABA imbalance, the root cause of many rare pediatric disorders, which share common clinical manifestations including developmental delay, autism, and epilepsy.
Because we know precisely where these genes are and what they do, replacing them (by gene replacement therapy and gene editing) to achieve GABA balance is a realistic therapeutic goal.
Why GALIBRA?
We leverage strong partnerships with leading academic institutes and patient advocacy groups to streamline bench to bedside translation of novel disease-modifying therapies.
Our approach is RAPID:
- R - research-oriented: our data-driven approach maximizes safety and efficacy
- A - accessibility: we work closely with patient communities and welcome feedback
- P - patient-focused: we goal is to improve patient quality of life
- I - innovative: our work stems from state-of-the-art technology with strong scientific foundation
- D - deep knowledge: we understand detailed disease mechanisms and clinical relevance
Pipeline
Leadership
